The Role of Eosinophils as a Biomarker to Inform Treatment Decisions for Patients With COPD
Blood eosinophil count is becoming increasingly recognized by the respiratory specialist community as a clinically relevant biomarker to help estimate affective management strategies, but the use is still widely debated. Nathaniel Marchetti, DO, answers questions about the role of eosinophils as a biomarker to inform treatment decisions for patients with COPD.

A Pragmatic Guide to Smoking Cessation
In this commentary, Michael J. Bloch, MD, writes about smoking as a risk factor for coronary heart disease and stroke, the need for clinicians to devote time and resources to smoking cessation interventions in their patients, and recommendations for smoking cessation interventions.

How the Growing Impact of Wildfires May Affect Pediatric Respiratory Outcomes
Adults use health care services more frequently when they are exposed to wildfire smoke, but the use among children is not as clear. Sydney Leibel, MD, MPH, from Rady Children and Hospital, answers our questions about the trends in pediatric respiratory visits during a recent California wildfire.

 Diagnosis, Management, Immunotherapy Options for Patients With Allergic Asthma
The most common type of asthma is allergic asthma, with about 60% of asthma cases caused by allergies. Sean P. Duffy, MD, answers questions about the diagnosis and management of allergic asthma, as well as the immunotherapy options available for these patients.

Exacerbations Increased After Discontinuing Long-term Use of Mepolizumab for Severe Eosinophilic Asthma
While the long-term safety and efficacy of mepolizumab have been studied, gaps in the literature have remained on the clinical impact of stopping mepolizumab after long-term use. Researchers examined how stopping this medication impacted the risk of exacerbations and asthma control.